Results 71 to 80 of about 11,060 (223)

First‐in‐human outpatient management of recurrent NMIBC with the Multi4 instrument

BJU International, EarlyView.
Objectives To evaluate the feasibility, safety and diagnostic performance of outpatient management of recurrent non‐muscle‐invasive bladder cancer (NMIBC) under local anaesthesia using the Multi4 instrument, a series of preclinical studies were performed followed by a first‐in‐human clinical investigation.
Miden Melle‐Hannah, Henrik Kjölhede, Henrik Bäckdahl, Martin E. Johansson, Joakim Håkansson   +4 more
wiley   +1 more source

Implantable cardioverter defibrillators: Uses, abuses, gains and complications

SA Heart Journal, 2017
Sudden cardiac death (SCD) due to a ventricular arrhythmia is one of the most common causes of death, yet its management continues to be a challenge. Controlled clinical trials have provided evidence that implantable cardioverter defibrillators (ICDs ...
Weiwei Li, Brian Olshansky
doaj   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Pacemakers and implantable cardioverter defibrillators [PDF]

Anaesthesia, 2006
Summary An increasing number of patients are now treated cardiac pacemakers and implantable cardioverter defibrillators and the technology of these is constantly changing. It is vital to have a good understanding of how they function and what the real risks are.
openaire   +2 more sources

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Intra-Abdominal Hemorrhage Triggering Inappropriate Therapy From a Subcutaneous Defibrillator

JACC: Case Reports
The SMART Pass filter (Boston Scientific) aims to reduce inappropriate shocks (IASs) from subcutaneous implantable cardioverter-defibrillators by filtering out low-frequency signals such as T waves.
Michael M. Malaty, MBBS, Max Ray, MBBS, David Ferreira, MBBS, Gwilym M. Morris, BMBCh, PhD, Nicholas Jackson, MBBS   +4 more
doaj   +1 more source

Safety and Utility of Smartphone‐Based Heart Monitors in Pediatric Patients With Cardiovascular Implantable Electronic Devices

Journal of Cardiovascular Electrophysiology, EarlyView.
Smartphone heart monitors in pediatric CIEDs: A pilot study. Smartphone heart monitors did not induce EMI in children with CIEDs, enabling reliable heart rate measurement and accurate identification of ventricular non‐captures. ABSTRACT Background Portable heart monitors enable on‐demand electrocardiogram (ECG) recordings and enhance symptom‐rhythm ...
Chun‐Lok Ho, Sit‐Yee Kwok, Sabrina S. L. Tsao, Yiu‐Fai Cheung   +3 more
wiley   +1 more source

Benefits of the Implantable Cardioverter-Defibrillator

Journal of the American College of Cardiology, 2008
The state-of-the-art review by Tung and colleagues provides a thoughtful perspective on balancing the benefits and risks of implantable cardioverter-defibrillator (ICD) therapy addressing the concerns of many caring physicians. In this response: 1) the clinical benefits of ICD therapy are reviewed using the evidence base resulting from controlled ...
openaire   +2 more sources

Terminal S Wave Pattern in Lead V3 as a Simple Marker for Ventricular Tachycardia Risk Stratification in Patients With Repaired Tetralogy of Fallot

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Introduction Patients with repaired tetralogy of Fallot (rTOF) remain at risk of ventricular tachycardia (VT). This risk is most commonly related to slow conduction within the septal isthmus, which is defined as the region between the ventricular septal defect (VSD) patch and adjacent valvular annuli.
Yuki Matsuoka, Miyako Igarashi, Naoto Kawamatsu, Yuto Iioka, Yoshihiro Harano, Yuki Komatsu, Tomoko Machino‐Ohtsuka, Hiro Yamasaki, Tomoko Ishizu   +8 more
wiley   +1 more source

Time‐Dependent Diagnostic Yield and Therapeutic Impact of Implantable Loop Recorders, Brugada Syndrome as the Exception

Journal of Cardiovascular Electrophysiology, EarlyView.
Diagnostic yield and therapeutic impact varied substantially according to the indication for implantation. Actionable diagnoses were concentrated in the early follow‐up period for syncope and palpitations, whereas late atrial fibrillation detection after cryptogenic stroke could still modify antithrombotic management. In contrast, patients with Brugada
Luigi Cocchiara, Benedetta Brescia, Procolo Marchese, Stefano Nardi, Luigi Argenziano, Gianmarco Arabia, Marco Micillo, Francesca Gennaro, Giovanni Mazzotta, Lucio Addeo, Alessandro Landolfi, Emiliano Calvi, Manuel Cerini, Alessio Nicolai, Teresa Strisciuglio, Pasquale Vergara, Giovanni Esposito, Antonio Rapacciuolo   +17 more
wiley   +1 more source